Kazuharu Kai, MD, PhD

Dr. Kazuharu Kai joined OncoC4 in February 2024 as the clinical lead for early-phase programs. He has extensive experience in industry drug development, having worked in cell therapy, cytokine therapeutics, small molecules, and immune oncology antibodies. Notably, he was part of the XPOVIO® (selinexor) supplementary NDA filing team for relapsed/refractory multiple myeloma at Karyopharm Therapeutics.

Before starting his industry career, Dr. Kai was a research faculty member at MD Anderson Cancer Center in Houston, TX, and a research instructor at Keio University in Tokyo. Prior to these appointments, he trained as a surgical oncologist at the University of Kumamoto and a regional hospital in Kumamoto, Japan, focusing on the care of patients with breast and gastrointestinal cancers.